Decheng Capital LLC Takes $4.56 Million Position in BioNTech SE (NASDAQ:BNTX)

Decheng Capital LLC purchased a new position in BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 40,000 shares of the company's stock, valued at approximately $4,558,000. BioNTech comprises approximately 1.0% of Decheng Capital LLC's holdings, making the stock its 20th largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in BNTX. Jones Financial Companies Lllp raised its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares during the last quarter. Allianz SE purchased a new position in shares of BioNTech in the fourth quarter worth $90,000. GAMMA Investing LLC raised its holdings in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in BioNTech during the fourth quarter valued at $137,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Truist Financial began coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. BMO Capital Markets lifted their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Morgan Stanley reduced their price target on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. Citigroup began coverage on BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price target for the company. Finally, HC Wainwright reduced their price target on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Trading Down 2.4 %

NASDAQ BNTX traded down $2.49 on Thursday, reaching $101.66. 420,140 shares of the company were exchanged, compared to its average volume of 992,026. The business's fifty day moving average price is $100.82 and its 200 day moving average price is $110.34. The stock has a market capitalization of $24.39 billion, a P/E ratio of -48.41 and a beta of 1.07. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year. Analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.